Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arlene M Gallagher

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
European Journal of Clinical Pharmacology|October 28, 2016
Evaluation of methods to estimate missing days' supply within pharmacy data of the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN)Kirsten J Lum, Craig W Newcomb, Jason A Roy, et al.
Pharmacoepidemiology and Drug Safety|December 19, 2017
Validity of diagnostic codes to identify hospitalizations for infections among patients treated with oral anti-diabetic drugsM Elle Saine, Mona Gizaw, Dena M Carbonari, et al.
Pharmacoepidemiology and Drug Safety|July 23, 2019
Concordance of hospitalizations between Clinical Practice Research Datalink and linked Hospital Episode Statistics among patients treated with oral antidiabetic therapiesM Elle Saine, Dena M Carbonari, Craig W Newcomb, et al.
Pharmacoepidemiology and Drug Safety|July 28, 2015
Use of demographic and pharmacy data to identify patients included within both the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN)Dena M Carbonari, M Elle Saine, Craig W Newcomb, et al.
BMC Pharmacology & Toxicology|April 19, 2015
Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugsM Elle Saine, Dena M Carbonari, Craig W Newcomb, et al.
Clinical Epidemiology|March 22, 2018
A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study)Jordi Castellsague, Josephina G Kuiper, Anton Pottegård, et al.
Drugs - Real World Outcomes|May 9, 2018
Use of Topical Tacrolimus and Topical Pimecrolimus in Four European Countries: A Multicentre Database Cohort StudyJosephina G Kuiper, Myrthe P P van Herk-Sukel, Jordi Castellsague, et al.
BMJ Open Diabetes Research & Care|September 8, 2017
Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomesVincent Lo Re, Dena M Carbonari, M Elle Saine, et al.
Plos One|June 27, 2019
Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencingJames S Floyd, Katarzyna M Bloch, Jennifer A Brody, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
European Journal of Clinical Pharmacology|October 28, 2016
Evaluation of methods to estimate missing days' supply within pharmacy data of the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN)Kirsten J Lum, Craig W Newcomb, Jason A Roy, et al.
Pharmacoepidemiology and Drug Safety|December 19, 2017
Validity of diagnostic codes to identify hospitalizations for infections among patients treated with oral anti-diabetic drugsM Elle Saine, Mona Gizaw, Dena M Carbonari, et al.
Pharmacoepidemiology and Drug Safety|July 23, 2019
Concordance of hospitalizations between Clinical Practice Research Datalink and linked Hospital Episode Statistics among patients treated with oral antidiabetic therapiesM Elle Saine, Dena M Carbonari, Craig W Newcomb, et al.
Pharmacoepidemiology and Drug Safety|July 28, 2015
Use of demographic and pharmacy data to identify patients included within both the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN)Dena M Carbonari, M Elle Saine, Craig W Newcomb, et al.
BMC Pharmacology & Toxicology|April 19, 2015
Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugsM Elle Saine, Dena M Carbonari, Craig W Newcomb, et al.
Clinical Epidemiology|March 22, 2018
A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study)Jordi Castellsague, Josephina G Kuiper, Anton Pottegård, et al.
Drugs - Real World Outcomes|May 9, 2018
Use of Topical Tacrolimus and Topical Pimecrolimus in Four European Countries: A Multicentre Database Cohort StudyJosephina G Kuiper, Myrthe P P van Herk-Sukel, Jordi Castellsague, et al.
BMJ Open Diabetes Research & Care|September 8, 2017
Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomesVincent Lo Re, Dena M Carbonari, M Elle Saine, et al.
Plos One|June 27, 2019
Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencingJames S Floyd, Katarzyna M Bloch, Jennifer A Brody, et al.
Pageof 3